NYPA and NYSERDA Announce New Battery Energy Storage
Analysis Shows How Cadenza Innovation’s Demonstration Project Can Serve as a Model for Grid Operators and
Globe Newswire17-02-2023, 03:38
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00